Angiex, Inc.

A Powerful New Approach To Curing Cancer

About this Event

Angiex is on a path to making cancer a non-lethal disease. Their lead product, AGX101, is founded on a special biology, a protein that is necessary for the growth of tumor blood vessels. By targeting that protein, AGX101 attacks tumor blood vessels, activates anti-tumor immunity, and kills invasive and metastatic tumor cells.

Phase 1 clinical trials are currently underway, with encouraging early results. AGX101 has enormous commercial potential, with a differentiated mechanism of action and extraordinary tumor homing abilities. It can potentially treat all solid cancers including such dangerous cancers as pancreatic, lung, breast, liver, stomach, kidney, ovarian, cervical, head and neck, and bladder.

Watch this Fireside Chat with Founder and CEO, Paul Jaminet, who will discuss how Angiex not only has the vision that no one should die of cancer, it has the practical means to achieve its vision.

Video On Demand

– Recorded

December 10

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.